First patients dosed in Bekinda IBS-D trialThe first patients have been dosed in a Phase II clinical study with RedHill Biopharma’s Bekinda 12 mg for diarrhoea-predominant irritable bowel syndrome (IBS-D). Click on this link for more information. #Pharmanews
The first patients have been dosed in a Phase II clinical study with RedHill Biopharma’s Bekinda 12 mg for diarrhoea-predominant irritable bowel syndrome (IBS-D). Click on this link for more information. #Pharmanews